Product Security and Coordinated Vulnerability Disclosure (CVD) Process

At Mammotome, we are a global team dedicated to advancing breast care. Our passion is driving innovative technologies that create efficiencies for clinicians, while never forgetting that at the heart of breast cancer journey is a patient. To achieve this, we uphold core values that define our responsibility to those we serve. Among them are an unwavering commitment to the safety and security of our instruments and services. Therefore, we believe in continuous improvement in order to address the ever-evolving privacy and cybersecurity landscape.

In response to potential threats to cybersecurity, Mammotome has formed a global product security expert team to assess vulnerabilities and determine responses within a coordinated vulnerability disclosure (CVD) process. These efforts allow the Mammotome to continually learn from vulnerability test information submitted to us by customers and security researchers.

For the latest product detail information, please visit Product Security Updates

Scope

This CVD process applies to the reporting of potential cybersecurity vulnerabilities in Mammotome products and services.
For customer support help requests, technical documents and regulatory contacts and notifications, please contact Mammotome Support.

Contact Information and CVD Submission Process

Potential security vulnerabilities or privacy issues with a Mammotome product should be reported to: [email protected]. We ask that you please refrain from including sensitive information (e.g., sample information, PHI, PII, etc.) as a part of any submissions to Mammotome. Please provide the following information in your submission:

• Your contact information (e.g., name, address, phone number, and email)
• Date and method of discovery
• Description of potential vulnerability
  • Product name
  • Version number
  • Configuration details
• Steps to reproduce
  • Tools and methods
  • Exploitation code
  • Privileges required
• Results or impact

What Happens Next

Upon receipt of a potential product vulnerability submission, Mammotome will:

• Acknowledge receipt of the submission within five (5) business days.
• Work with specialized product teams to evaluate and validate reported findings.
• Contact the submitter to request additional information, if needed.
• Take appropriate action.

Disclaimer

Mammotome considers it a top priority to protect the health and safety, as well as the personal information, of our customers' patients.

When conducting your security research, please avoid actions that could cause harm to patients or products. Note that vulnerability testing could negatively impact a product. As such, testing should not be conducted on active products in a clinical setting, and products subjected to security testing should not subsequently be used in a clinical setting. If there is any doubt, please contact a Mammotome representative.

Mammotome reserves the right to modify its coordinated vulnerability disclosure process at any time, without notice, and to make exceptions to it on a case-by-case basis. No particular level of response is guaranteed. However, if a vulnerability is verified.

CAUTION: Do not include sensitive information (e.g., sample information, PHI, PII, etc.) in any documents submitted to Mammotome. Comply with all laws and regulations in the course of your testing activities.

By contacting Mammotome, you agree that the information you provide will be governed by our site's Privacy Policy and Online Terms of Use.

Note: When sharing any information with Mammotome, you agree that the information you submit will be considered non-proprietary and non-confidential and that Mammotome is allowed to use such information in any manner, in whole or in part, without any restriction.